Global GLP-1 Weight Loss Drug Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP-1 Weight Loss Drug Market Research Report 2024
GLP-1 (Glucagon-Like Peptide-1) weight loss drugs are a class of drugs used to treat obesity and control weight. GLP-1 is a naturally occurring insulin-releasing hormone produced by cells in the small intestine after food ingestion and has multiple physiological effects, including stimulating insulin secretion and inhibiting gastric emptying, thereby slowing the passage of food through the gastrointestinal tract. GLP-1 weight loss drugs simulate the biological activity of GLP-1 and trigger a series of physiological reactions, which help reduce appetite, increase satiety, and reduce calorie intake, thereby helping people lose weight. This class of drugs is often used to treat obesity, especially in obese patients who are at risk for diabetes.
According to Mr Accuracy reports’s new survey, global GLP-1 Weight Loss Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029.
Key manufacturers engaged in the GLP-1 Weight Loss Drug industry include Novo Nordisk, AstraZeneca, Eli Lilly, Sanofi, BENEMAE, HANSOH PHARMLA, CHIATAI TIANQING, Tonghua Dongbao Pharmaceutical and Huadong Medicine, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GLP-1 Weight Loss Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Weight Loss Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Weight Loss Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
AstraZeneca
Eli Lilly
Sanofi
BENEMAE
HANSOH PHARMLA
CHIATAI TIANQING
Tonghua Dongbao Pharmaceutical
Huadong Medicine
Segment by Type
Injection
Oral
Online Pharmacy
Offline Pharmacy
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GLP-1 Weight Loss Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global GLP-1 Weight Loss Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029.
Key manufacturers engaged in the GLP-1 Weight Loss Drug industry include Novo Nordisk, AstraZeneca, Eli Lilly, Sanofi, BENEMAE, HANSOH PHARMLA, CHIATAI TIANQING, Tonghua Dongbao Pharmaceutical and Huadong Medicine, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GLP-1 Weight Loss Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Weight Loss Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP-1 Weight Loss Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
AstraZeneca
Eli Lilly
Sanofi
BENEMAE
HANSOH PHARMLA
CHIATAI TIANQING
Tonghua Dongbao Pharmaceutical
Huadong Medicine
Segment by Type
Injection
Oral
Segment by Application
Online Pharmacy
Offline Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GLP-1 Weight Loss Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices